Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

EGFR E709K

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

EGFR exon 19 deletion (79)

EGFR amplification (52)

EGFR exon 18 deletion (3)

EGFR exon 2-7 deletion + EGFR amplification (2)

EGFR amplification + ERBB2 amplification (1)

EGFR exon 19 deletion + HER-2 amplification (1)

EGFR exon 21 deletion (1)

EGFR T790M + exon 19 deletion (0)

EGFR amplifcation (0)

EGFR exon 19 deletion (79)

EGFR amplification (52)

EGFR exon 18 deletion (3)

EGFR exon 2-7 deletion + EGFR amplification (2)

EGFR amplification + ERBB2 amplification (1)

EGFR exon 19 deletion + HER-2 amplification (1)

EGFR exon 21 deletion (1)

EGFR T790M + exon 19 deletion (0)

EGFR amplifcation (0)

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer (NCI-2019-05913) (NCT04085315)

Phase 1

Collin Blakely

Collin Blakely

Recruiting

Phase 1

Collin Blakely

Recruiting

Last update posted :

06/10/2024

Initiation :

11/12/2019

Primary completion :

12/31/2026

Completion :

12/31/2026

EGFR

|

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR E709K • EGFR exon 19 insertion • EGFR H835L • EGFR L833V • EGFR V834L

|

Tagrisso (osimertinib) • alisertib (MLN8237)